

CARDIOMYOPATHY

Hanna K. AL-Makhamreh, MD FACC
Associate of Professor of Cardiology
University of Jordan

- ▶ *Cardiomyopathies are a heterogeneous group of diseases of the myocardium associated with mechanical and/or electric dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently are genetic. Cardiomyopathies either are confined to the heart or are part of generalized systemic disorders.”*

DEFINITION

- ▶ M refers to the phenotype (eg, DCM and HCM)
- ▶ O refers to organ involvement (eg, with/without extracardiac involvement)
- ▶ G refers to genetic transmission (eg, autosomal dominant or recessive)
- ▶ E refers to etiology (eg, genetic with diseased gene and mutation, if known),
- ▶ S refers to disease stage.


MOGES CLASSIFICATION

CARDIOMYOPATHY

WHO Classification

anatomy & physiology of the LV

1. Dilated
 - Enlarged
 - Systolic dysfunction
2. Hypertrophic
 - Thickened
 - Diastolic dysfunction
3. Restrictive
 - Diastolic dysfunction
4. Arrhythmogenic RV dysplasia
 - Fibrofatty replacement
5. Unclassified
 - Fibroelastosis
 - LV noncompaction



Dilatation of the Left or both ventricles that is not explained by abnormal loading conditions or coronary artery disease. DCM is characterized by cardiac enlargement with ventricular walls of approximately normal thickness and varying extents of fibrosis. The patients develop progressive HF with reduced ejection fraction, tachyarrhythmias, and an increased risk of sudden death. .Mitral and tricuspid regurgitation because of annular dilatation are frequent and intensify the hemodynamic burden.

DCM

A decorative graphic consisting of several parallel white lines of varying lengths, slanted diagonally from the bottom right towards the top right, set against the blue background.

DCM: ETIOLOGY

Ischemic

Valvular

Hypertensive

Familial

Idiopathic

Inflammatory

Infectious

Viral – Cox B, CMV, HIV

Rickettsial - Lyme Disease

Parasitic - Chagas' Disease, Toxoplasmosis

Non-infectious

Collagen Vascular Disease (SLE, RA)

Peripartum

Toxic

Alcohol, Anthracyclins (adriamycin), Cocaine

Metabolic

Endocrine –thyroid dz, pheochromocytoma, DM, acromegaly,

Nutritional

Thiamine, selenium, carnitine

Neuromuscular (Duchene's Muscular Dystrophy--x-linked)

DILATED CARDIOMYOPATHY


- Dilation *and* impaired contraction of ventricles:
 - Reduced *systolic* function with or without heart failure
 - Characterized by myocyte damage
 - Multiple etiologies with similar resultant pathophysiology
- **idiopathic**
 - incidence of idiopathic dilated CM 5-8/100,000
 - incidence likely higher due to mild, asymptomatic cases
 - 3X more prevalent among males and African-Americans

DCM: INHERITED

Familial cardiomyopathy

- ▶ 30% of idiopathic
- ▶ Inheritance patterns
 - ▶ Autosomal dom (most common)/rec, x-linked, mitochondrial
- ▶ Associated phenotypes:
 - ▶ Skeletal muscle abn., neurologic, auditory
- ▶ Mechanism:
 - ▶ Abnormalities in:
 - ▶ Energy production
 - ▶ Contractile force generation
 - ▶ Specific genes coding for:
 - ▶ **The gene that encodes titin—the giant protein that controls the stiffness of the sarcomere—is the most common and is responsible for ≈20% of cases of familial DCM.**

DCM-MYOCARDITIS



- ▶ Acute viral myocarditis
- ▶ Coxsackie B or echovirus
- ▶ Self-limited infection in young people
- ▶ Mechanism:
- ▶ Myocyte cell death and fibrosis
- ▶ Immune mediated injury
- ▶ BUT no change with immunosuppressive drugs

DCM: INFECTIOUS



- inflammation, and immune reactions are involved in the pathobiology of many cardiomyopathies
- Noninfectious, immune-driven causes of myocarditis include allergic reactions to drugs, Kawasaki disease, systemic lupus erythematosus, and Löffler endocarditis
- CMR provides a powerful tool in the recognition and assessment
- Gold standard is Biopsy

NON-INFECTIOUS MYOCARDITIS

A decorative graphic consisting of several parallel white lines of varying lengths, slanted diagonally from the bottom right towards the top right, set against a blue background.

DCM: TOXIC


Alcoholic cardiomyopathy

- ▶ Chronic use.....80gm/day for 5 years or more
- ▶ Reversible with abstinence
- ▶ 25-30% of NICMP
- ▶ Mechanism:
 - ▶ Myocyte cell death and fibrosis
 - ▶ Directly inhibits:
 - ▶ mitochondrial damage
 - ▶ ROS increased leading to oxidation of protein,DNA...


DCM: PERIPARTUM

Diagnostic Criteria

- ▶ 1 mo pre, 6 mos post
- ▶ Echo: LV dysfunction
- ▶ Epidemiology/Etiology
- ▶ 1:4000 women
- ▶ Risk factors: Advanced age, AA, pre eclampsia
Multiple pregnancies,
Alcohol, Tobacco
- ▶ Proposed mechanisms:
 - ▶ Inflammation



Pathobiology of peripartum cardiomyopathy.




Pathobiology of peripartum cardiomyopathy. Secretion of prolactin by the anterior pituitary gland, upregulation of endothelial microRNA-146a (miRNA-146a), and placental secretion of soluble fms-like tyrosine kinase receptor 1 (sFlt-1) lead to endothelial dysfunction and cardiomyocyte death; genetic susceptibility is also present in some patients. VEGF=vascular endothelial growth factor. See text for details.


IDIOPATHIC CARDIOMYOPATHY



ISCHEMIC CM



PROGNOSIS DEPENDS ON ETIOLOGY



1230 pts. referred for unexplained CM. Felker GM. NEJM 2000;342:1077

HYPERTROPHIC CARDIOMYOPATHY

Left ventricular hypertrophy not due to pressure overload

Hypertrophy is variable in both severity and location:

- asymmetric septal hypertrophy
- symmetric (non-obstructive)
- apical hypertrophy

Vigorous systolic function, but impaired diastolic function
impaired relaxation of ventricles
elevated diastolic pressures

prevalence as high as 1/500 in general population
mortality 1% /y

ETIOLOGY


Familial in ~ 55% of cases with autosomal dominant transmission
Mutations in one of 4 genes encoding proteins of cardiac sarcomere
account for majority of familial cases

β -MHC (Beta Myocin Heavy
Chain)


cardiac troponin T

myosin binding protein C


α -tropomyosin




HYPERTROPHIC CARDIOMYOPATHY



HYPERTROPHIC CARDIOMYOPATHY



PATHOPHYSIOLOGY




HCM WITH OUTFLOW OBSTRUCTION

Dynamic LVOT obstruction (may not be present at rest)

SAM (systolic anterior motion of mitral valve)

LVOT Obstruction \Rightarrow LVOT gradient
 \Rightarrow \uparrow wall stress \Rightarrow \uparrow MVO₂ \Rightarrow ischemia



Dyspnea and angina more related to diastolic dysfunction than to outflow tract obstruction

Syncope: LVOT obstruction (failure to increase CO during exercise or after vasodilatory stress) or arrhythmia.

PHYSICAL EXAM

Bisferiens pulse (“spike and dome”)

S4 gallop

Crescendo/Decrescendo systolic ejection murmur

HOCM vs. Valvular AS

Valsalva (↓preload, ↓ afterload)

Squatting (↑ preload, ↑ afterload)

Standing (↓preload, ↓ afterload)

Intensity of murmur

HOCM

↑

↓

↑

AS

↓

↑

↓

Holosystolic apical blowing murmur of mitral regurgitation

DIAGNOSTIC STUDIES


- ▶ EKG
 - ▶ NSR
 - ▶ LVH
 - ▶ septal Q waves
- ▶ 2D-Echocardiography
 - ▶ LVH; septum $>1.4x$ free wall
 - ▶ LVOT gradient by Doppler
 - ▶ Systolic anterior motion of the mitral valve
- ▶ Cardiac Catheterization
 - ▶ LVOT gradient and pullback
 - ▶ provocative maneuvers
 - ▶ Brockenbrough phen

HCM-ASH using contrast

A series of white diagonal lines of varying lengths and thicknesses, located in the bottom right corner of the slide, extending from the bottom edge towards the top right.


CARDIAC CATHETERIZATION

LV pullback



Brockenbrough-Braunwald Sign


failure of aortic pulse pressure to rise post PVC



Provocative maneuvers:

Valsalva

amyl nitrate inhalation



TREATMENT

For symptomatic benefit

β -blockers

↓ mvO₂


↓ gradient (exercise)

↓ arrhythmias

Calcium Channel blockers

AICD for sudden death

Antibiotic prophylaxis for endocarditis



HCM: SURGICAL TREATMENT

For severe symptoms with high outflow gradient

Myomyectomy

removal of small portion of upper IV septum

+/- mitral valve replacement


5 year symptomatic benefit in ~ 70% of patients

ETOH septal ablation


AICD to prevent sudden death

WALL THICKNESS AND SUDDEN DEATH IN HCM

Incidence of Sudden Death
(per 1,000 person/yr)




AICD INDICATIONS

- Survivors of SCD
 - Non-Sustained VT
 - Family hx of SCD in young family members
 - Septal thickness ≥ 30 mm
 - Unexplained syncope
- 

HCM VS ATHLETES HEART


▶ Athlete's heart

- ▶ DEFINITION: Symmetric $<14\text{mm}$
 - ▶ No obstruction
 - ▶ LA size $<4\text{cm}$
 - ▶ Reversible if exercise was stopped for 3 months
 - ▶ Maintaining LV cavity
- 
- A decorative graphic consisting of several parallel white lines of varying lengths, slanted upwards from left to right, located in the bottom right corner of the slide.


RESTRICTIVE CARDIOMYOPATHY

Characterized by:

- impaired ventricular filling due to an abnormally stiff (rigid) ventricle
- normal systolic function
- intraventricular pressure rises precipitously with small increases in volume



Causes : infiltration of myocardium by abnormal substance
fibrosis or scarring of endocardium



Amyloid infiltrative CM

**TABLE 4. CAUSES OF RESTRICTIVE
CARDIOMYOPATHY.**

Myocardial

Noninfiltrative disorders

- Idiopathic disease
- Familial disease
- Hypertrophy
- Scleroderma
- Diabetes mellitus
- Pseudoxanthoma elasticum

Infiltrative disorders

- Amyloidosis
- Sarcoidosis
- Gaucher's disease
- Hurler's syndrome
- Fatty infiltration

Storage disorders

- Hemochromatosis
- Fabry's disease
- Glycogen storage disease

Endomyocardial

- Endomyocardial fibrosis
 - Hyper eosinophilic (Löffler's) syndrome
 - Carcinoid syndrome
 - Metastatic cancer
 - Exposure to radiation
 - Toxins
 - Anthracycline (doxorubicin or daunorubicin)
 - Serotonin
 - Methysergide
 - Ergotamine
 - Mercurial agents
 - Busulfan
-

AMYLOIDOSIS


Amyloidosis is caused by protein misfolding in which extracellular aggregates of the misfolded proteins form fibrils

Immunoglobulin light chain Amyloid and Transthyretin ATTR
Amyloid

Restriction caused by replacement of normal myocardial contractile elements by infiltrative interstitial deposits



AMYLOID CARDIOMYOPATHY



- ▶ CMR is a sensitive diagnostic technique for amyloid cardiomyopathy. Late gadolinium enhancement (LGE) has been shown in >80% of patients, including patients without evidence of this disorder by echocardiography
- ▶ positron emission tomography (PET).
- ▶ A definitive diagnosis of this condition still requires histological verification.

AMYLOID



- ▶ Therapy of light-chain amyloidosis includes autologous bone marrow stem cell transplantation and drugs that include dexamethasone, melphalan, immunomodulatory agents, and the proteasome inhibitor bortezomib.

AMYLOID TREATMENT


SARCOIDOSIS

- Sarcoidosis is an inflammatory condition in which non-caseating granulomas involve multiple organs
- Restriction
- Conduction System Disease
- Ventricular Arrhythmias (Sudden Cardiac Death)

Current therapy involves glucocorticoids, supplemented by other immunosuppressive agents if necessary.


ENDOMYOCARDIAL FIBROSIS

Endemic in parts of Africa, 15-25% of cardiac deaths in equatorial Africa
hypereosinophilic syndrome (Löffler's endocarditis)



Thickening of basal inferior wall
endocardial deposition of thrombus
apical obliteration
mitral regurgitation
80-90% die within 1-2 years

PATHOPHYSIOLOGY OF RESTRICTION



Elevated systemic and pulmonary venous pressures
right and left sided congestion
reduced ventricular cavity size with ↓SV and ↓CO

CLINICAL FINDINGS

Dyspnea

Orthopnea/PND

Peripheral edema

Ascites/Hepatomegaly

Fatigue/ ↓exercise tolerance

Clinically mimics constrictive Pericarditis




DIAGNOSTIC STUDIES



2D-Echo/Doppler-
mitral in-flow velocity
rapid early diastolic filling

Catheterization –
diastolic pressure equilibration
restrictive vs constrictive
hemodynamics

Endomyocardial biopsy-
definite Dx of restrictive pathology



CARDIAC CATHETERIZATION



Prominent y descent
rapid atrial emptying
then abrupt cessation of blood flow due to non-compliant myocardium

“dip and plateau”
rapid ventricular filling

TREATMENT

Treat underlying cause

Amyloid (melphalan/prednisone/colchicine)

Endomyocardial Fibrosis (steroids, cytotoxic drugs, MVR)

Hemochromatosis (chelation, phlebotomy)

Sarcoidosis (steroids)

Diuretics, and other treatment options for HF

Pacemaker for conduction system disease

Anticoagulation for thrombus

Transplant is the best treatment


ARRHYTHMOGENIC RV DYSPLASIA (ARVD)

- ▶ Myocardium of RV free wall replaced:
 - ▶ Fibrofatty tissue
 - ▶ Regional wall motion/function is reduced
- ▶ Ventricular arrhythmias
 - ▶ SCD in young

- ▶ Abnormalities in intercellular adhesion molecules, desmosomes, cause cell death and fibrofatty replacement.
- ▶ These abnormalities are caused by mutations in genes, such as *PKP2* and *DSP*, encoding plakophilin 2 and desmoplakin, respectively. Inheritance in most cases is by Mendelian dominant transmission.
- ▶ The epsilon wave of delayed repolarization following the QRS complex is helpful in diagnosis.
- ▶ Contrast-enhanced cardiac magnetic resonance (CMR)

ARVD






ARVD ECG-EPSILON WAVE

- ▶ Treatment consists of the cessation of heavy physical exertion and competitive athletics.
- ▶ recurrent ventricular tachycardia, epicardial catheter ablation may be effective. Implantation of a cardioverter/defibrillator is indicated in patients who have experienced ventricular fibrillation or refractory ventricular tachycardia.
- ▶ Patients with intractable HF may require cardiac transplantation.
- ▶ Genetic screening should be performed in family members

ARVD TREATMENT

MRI: RV DYSPLASIA




LV NONCOMPACTION

Diagnostic Criteria

- ▶ Prominent trabeculations, deep recesses in LV apex

Prognosis and Treatment

- ▶ Increased risk of CHF, VT/SCD, thrombosis
- ▶ Hereditary risk
 - ▶ Screening of offspring



LV NONCOMPACTION



THANK YOU

